| Market Capitalization (Millions $) |
78 |
| Shares
Outstanding (Millions) |
24 |
| Employees |
133 |
| Revenues (TTM) (Millions $) |
5 |
| Net Income (TTM) (Millions $) |
-61 |
| Cash Flow (TTM) (Millions $) |
11 |
| Capital Exp. (TTM) (Millions $) |
0 |
Biolinerx Ltd
BioLineRx Ltd is a clinical-stage biopharmaceutical company that specializes in the development of innovative therapies for a wide range of diseases. The company was founded in 2003 and is headquartered in Modi'in, Israel. BioLineRx operates globally with offices in the United States, Europe, and Asia, and is listed on the NASDAQ and Tel Aviv Stock Exchanges.
BioLineRx's focus is on the development of novel, therapeutics for oncology, immunology, and other disease areas, with a particular focus on drugs that target unmet medical needs, including rare and hard-to-treat diseases. The company's pipeline consists of both in-house development programs and collaborations with other leading pharmaceutical and biotech companies.
BioLineRx's lead product candidate, BL-8040, is a novel cancer therapy that targets both cancer stem cells and the tumor microenvironment. It is currently being evaluated in multiple clinical trials for hematological malignancies and solid tumors. The company's other pipeline candidates include novel immunotherapies, gene therapies, and small molecules targeting various cancers, inflammatory and autoimmune diseases, and infectious diseases.
BioLineRx is also actively engaged in collaborations with other leading pharmaceutical and biotech companies, including Novartis, Genentech, Merck, and Roche. These collaborations leverage BioLineRx's expertise in drug discovery and development to advance promising therapeutics through clinical trials and regulatory approval.
The company is committed to leveraging cutting-edge technologies in its drug development programs, including genomics, proteomics, and computational biology. BioLineRx has a strong intellectual property portfolio, with more than 60 patents and patent"},"finish
Company Address: 2 HaMa?ayan Street Modi?in 7177871
Company Phone Number: 642-9100 Stock Exchange / Ticker: BLRX
|
5.75%